Growth hormone (GH) is under dual hypothalamic influence by GH-releasing hormone (GHRH), which stimulates, and somatostatin (SRIH), which inhibits, GH secretion. Specific receptors for SRIH are expressed on somatotroph adenomas. Expression of this hormone in GH tumors appears to be reduced compared to that in the normal pituitary (1) . Furthermore, nearly one-third of somatotroph adenomas are associated with a somatic mutation in the membrane coupling Gs protein (2) . This defect results in constitutive activation of adenylate cyclase activity and hence increased intracellular cAMP levels. The inhibitory effects of SRIH on GH and cAMP production (3) , therefore, support the rationale for the use of SRIH in the management of GH-producing pituitary adenomas. Indeed, SRIH lowers GH secretion in normal and acromegalie patients (4, 5) , but use of this peptide is limited owing to its short half-life.
Current treatment options for patients with GH- secreting pituitary adenomas include surgical resection (6) , external radiotherapy (7) or medical therapy (8) . None of these approaches independently provides com¬ plete correction of the tumor mass and GH hypersecretory effects associated with these adenomas. The SRIH analog octreotide is an effective GH-lowering agent that has been used to control GH hypersécrétion in patients with acromegaly (9, 10) . We have reported previously the cellular effects induced by octreotide on somatotroph adenomas (11 (2) . The presence of this mutation has been associated with variable plasma GH levels (2, 13 ). In the current study, we found no difference in basal GH or IGF-I levels between patients harboring DG adenomas and those with SG adenomas. As GH and IGF-I levels usually correlate with pituitary tumor size (10), the lack of such difference in our study may reflect the inclusion of only patients with macroadenomas. While the therapeutic response to octreotide has not previously been exam¬ ined specifically with respect to the presence of this mutation, GH-producing adenomas with high basal adenylyl cyelase levels display greater inhibition of adenylyl cyelase in vitro and GH secretion in vivo by octreotide (3) . Our data agree with these earlier findings inasmuch as greater inhibition of GH by octreotide was noted in DG adenomas, which have been described to be associated with Gs mutations (2) .
The mechanism of action of octreotide on somato¬ troph adenomas appears to involve inhibition of hormone release without alteration of GH gene transcription (14) . This is consistent with our previous data indicating that the diameters and cytoplasmic volume densities of secretory granules are increased in somatotroph adenomas resected from patients who were treated with octreotide, thus indicating retention of and inhibition of release of GH (11, 12 
